Gastric Cancer

>

Latest News

Subgroup analyses from the phase 3 CheckMate 649 and KEYNOTE-859 clinical trials showed little OS difference between investigational and chemotherapy arms.
FDA Limits Pembrolizumab/Nivolumab in PD-L1–Low Gastric Cancer Indications

June 22nd 2025

Subgroup analyses from the phase 3 CheckMate649 and KEYNOTE-859 clinical trials showed little OS difference between investigational and chemotherapy arms.

Phase 2 data may support nivolumab plus low-dose ipilimumab as a promising option in patients with microsatellite instability–high gastric cancer.
Frontline Nivolumab Combo Shows Enduring Activity in MSI-H Gastric Cancer

June 10th 2025

Satri-Cel Improves Survival vs Physician’s Choice in Pretreated Gastric/GEJ Cancer
Satri-Cel Improves Survival vs Physician’s Choice in Pretreated Gastric/GEJ Cancer

June 9th 2025

T-DXd Emerges as New Standard of Care for Second-Line HER2+ Gastric/GEJ Cancer
T-DXd Emerges as New Standard of Care for Second-Line HER2+ Gastric/GEJ Cancer

May 31st 2025

Antitumor activity was observed in patients with gastroesophageal adenocarcinoma treated with the combination regardless of chemotherapy type.
Zanidatamab Displays Safety, Efficacy in HER2-Expressing Gastric Cancer

May 19th 2025

Video Interviews
Podcasts

More News